In this video Professor Faragher talks about senescent cells, how they form and some of their effects on the body. Professor Faragher's audio freezes a couple of times for a short time. Apologies for the interruption. Professor Richard Faragher is Professor of biological gerontology at the University of Brighton and has been studying the relationship between cellular senescence and aging for more than 30 years. He is one of the leading experts on ageing and has become one of only three British academics to ever win a Glenn Award for research. He recently led a team showing the reversal of cellular senescence with derivatives of resveratrol. If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan 15% off Bulletproof products at https://www.bulletproof.com/ with discount code HEALTHSPAN15.

In this video Dr Faragher talks about why we age including some aspects of human history that make us unique. Professor Faragher's audio freezes a couple of times for a short time. Apologies for the interruption. Professor Richard Faragher is Professor of biological gerontology at the University of Brighton and has been studying the relationship between cellular senescence and aging for more than 30 years. He is one of the leading experts on ageing and has become one of only three British academics to ever win a Glenn Award for research. He recently led a team showing the reversal of cellular senescence with derivatives of resveratrol. If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan 15% off Bulletproof products at https://www.bulletproof.com/ with discount code HEALTHSPAN15.

In this video Dr Perlmutter about some of the other things which can impact our uric acid levels, such as stress, lack of sleep and an unhealthy microbiome. Dr. Perlmutter is a Board-Certified Neurologist and six-time New York Times bestselling author. His books have been published in 32 languages and include the bestseller Grain Brain. His newly published book, Drop Acid, focuses on the pivotal role of uric acid in metabolic diseases. He is recognized internationally as a leader in the field of nutritional influences in neurological disorders. Dr Perlmutter's website https://www.drperlmutter.com/ His book is available on Amazon and other locations https://tinyurl.com/2p9x57kj If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan 15% off Bulletproof products at https://www.bulletproof.com/ with discount code Healthspan15.

In this video Dr Perlmutter talks more generally about diet and uric acid, particularly purines and alcohol. He also discusses supplements such as quercetin that can help reduce our levels of uric acid. Dr. Perlmutter is a Board-Certified Neurologist and six-time New York Times bestselling author. His books have been published in 32 languages and include the bestseller Grain Brain. His newly published book, Drop Acid, focuses on the pivotal role of uric acid in metabolic diseases. He is recognized internationally as a leader in the field of nutritional influences in neurological disorders. Dr Perlmutter's website https://www.drperlmutter.com/ His book is available on Amazon and other locations https://tinyurl.com/2p9x57kj If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan https://shop.bulletproof.com/   15% off Bulletproof supplements with discount code: Healthspan15

In this video Dr Perlmutter diet and uric acid with a particular focus on fructose, how it is metabolized and how ubiquitous it is in our food supply. Dr. Perlmutter is a Board-Certified Neurologist and six-time New York Times bestselling author. His books have been published in 32 languages and include the bestseller Grain Brain. His newly published book, Drop Acid, focuses on the pivotal role of uric acid in metabolic diseases. He is recognized internationally as a leader in the field of nutritional influences in neurological disorders. Dr Perlmutter's website https://www.drperlmutter.com/ His book is available on Amazon and other locations https://tinyurl.com/2p9x57kj If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan

In this video Dr Perlmutter discusses the optimal level of uric acid and how to measure. He also covers how uric acid levels change with age and fasting. Dr. Perlmutter is a Board-Certified Neurologist and six-time New York Times bestselling author. His books have been published in 32 languages and include the bestseller Grain Brain. His newly published book, Drop Acid, focuses on the pivotal role of uric acid in metabolic diseases. He is recognized internationally as a leader in the field of nutritional influences in neurological disorders. Dr Perlmutter's website https://www.drperlmutter.com/ His book is available on Amazon and other locations https://tinyurl.com/2p9x57kj If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan

In this video Dr Perlmutter introduces uric acid, where it comes from and its impact on our metabolism and overall health. Dr. Perlmutter is a Board-Certified Neurologist and six-time New York Times bestselling author. His books have been published in 32 languages and include the bestseller Grain Brain. His newly published book, Drop Acid, focuses on the pivotal role of uric acid in metabolic diseases. He is recognized internationally as a leader in the field of nutritional influences in neurological disorders. Dr Perlmutter's website https://www.drperlmutter.com/ His book is available on Amazon and other locations https://tinyurl.com/2p9x57kj If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan

In this video Dr. Kirkland talks about the future of aging and how the biology of aging affects everyone and should not be thought of as only relevant to older people. He also discusses the path of bringing senolytics to wider use. Dr. James Kirkland is Director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic and Noaber Foundation Professor of Aging Research. Dr. Kirkland's research focuses on cellular senescence, age-related adipose tissue and metabolic dysfunction, and development of agents and strategies for targeting fundamental aging mechanisms to treat age-related chronic diseases and disabilities and to extend healthspan. He published the first article about drugs that clear senescent cells, senolytic agents. A novel, mechanism-based, hypothesis-driven drug development paradigm was used to discover senolytic drugs. Based on the observation that senescent cells release factors that cause apoptosis of the cells around them, yet are themselves resistant to apoptosis, Dr. Kirkland hypothesized that senescent cells utilize senescent cell anti-apoptotic pathways (SCAPs) for protection from their own senescence-associated secretory phenotype (SASP). Using bioinformatics analyses of senescent vs. non-senescent cells and RNA interference, Dr. Kirkland identified these SCAPs and verified their importance for senescent cell survival. Dr. Kirkland used bioinformatics approaches to identify agents that target key nodes across the SCAP network and demonstrated these drugs are senolytic in rodent and human cultured cells and mice in vivo. These senolytic drugs include Dasatinib (D), Quercetin (Q), Fisetin, Navitoclax, and related compounds. Dr. Kirkland showed these agents delay, prevent, or alleviate multiple disorders in mouse models of human chronic diseases and aging phenotypes. Conditions alleviated in mouse models include frailty, diabetes, hepatic steatosis, cirrhosis, renal dysfunction, neuropsychiatric disorders, dementias, pulmonary fibrosis, osteoporosis, osteoarthritis, retinal degeneration, diastolic dysfunction, cardiac ischemia, vascular hyporeactivity, infertility, and skin disorders, among others. He demonstrated that intermittent, orally administered senolytics reduce senescent cell abundance in adipose tissue and blood markers of senescent cell burden in blood of patients with diabetic kidney disease. He and collaborators found that a brief course of senolytics enhances physical function and reduces frailty in patients with idiopathic pulmonary fibrosis, a fatal, cellular-senescence-driven disease for which available treatments have been unsatisfactory. Multiple clinical trials are currently underway of the senolytics that Dr. Kirkland discovered. He is a scientific advisory board member for several companies and academic organizations. In addition to being President-Elect of AFAR, he has been a member of the National Advisory Council on Aging of the National Institutes of Health, and past chair of the Biological Sciences Section of the Gerontological Society of America. He holds honorary appointments at Boston University and the University of Groningen in the Netherlands. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism. If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan

In this video Dr. Kirkland talks about what we can do to reduce our senescent cell burden with lifestyle choices and how there is a grouping of health organizations measuring health markers across multiple trials to gather data on aging. Dr. James Kirkland is Director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic and Noaber Foundation Professor of Aging Research. Dr. Kirkland's research focuses on cellular senescence, age-related adipose tissue and metabolic dysfunction, and development of agents and strategies for targeting fundamental aging mechanisms to treat age-related chronic diseases and disabilities and to extend healthspan. He published the first article about drugs that clear senescent cells, senolytic agents. A novel, mechanism-based, hypothesis-driven drug development paradigm was used to discover senolytic drugs. Based on the observation that senescent cells release factors that cause apoptosis of the cells around them, yet are themselves resistant to apoptosis, Dr. Kirkland hypothesized that senescent cells utilize senescent cell anti-apoptotic pathways (SCAPs) for protection from their own senescence-associated secretory phenotype (SASP). Using bioinformatics analyses of senescent vs. non-senescent cells and RNA interference, Dr. Kirkland identified these SCAPs and verified their importance for senescent cell survival. Dr. Kirkland used bioinformatics approaches to identify agents that target key nodes across the SCAP network and demonstrated these drugs are senolytic in rodent and human cultured cells and mice in vivo. These senolytic drugs include Dasatinib (D), Quercetin (Q), Fisetin, Navitoclax, and related compounds. Dr. Kirkland showed these agents delay, prevent, or alleviate multiple disorders in mouse models of human chronic diseases and aging phenotypes. Conditions alleviated in mouse models include frailty, diabetes, hepatic steatosis, cirrhosis, renal dysfunction, neuropsychiatric disorders, dementias, pulmonary fibrosis, osteoporosis, osteoarthritis, retinal degeneration, diastolic dysfunction, cardiac ischemia, vascular hyporeactivity, infertility, and skin disorders, among others. He demonstrated that intermittent, orally administered senolytics reduce senescent cell abundance in adipose tissue and blood markers of senescent cell burden in blood of patients with diabetic kidney disease. He and collaborators found that a brief course of senolytics enhances physical function and reduces frailty in patients with idiopathic pulmonary fibrosis, a fatal, cellular-senescence-driven disease for which available treatments have been unsatisfactory. Multiple clinical trials are currently underway of the senolytics that Dr. Kirkland discovered. He is a scientific advisory board member for several companies and academic organizations. In addition to being President-Elect of AFAR, he has been a member of the National Advisory Council on Aging of the National Institutes of Health, and past chair of the Biological Sciences Section of the Gerontological Society of America. He holds honorary appointments at Boston University and the University of Groningen in the Netherlands. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism. If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan

In this video Dr. Kirkland talks about the senolytics that the Mayo Clinic is using in the on going trials, dasatinib, Fisetin and Quercetin. He also talks about the way the work and the schedule to taking them Dr. James Kirkland is Director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic and Noaber Foundation Professor of Aging Research. Dr. Kirkland's research focuses on cellular senescence, age-related adipose tissue and metabolic dysfunction, and development of agents and strategies for targeting fundamental aging mechanisms to treat age-related chronic diseases and disabilities and to extend healthspan. He published the first article about drugs that clear senescent cells, senolytic agents. A novel, mechanism-based, hypothesis-driven drug development paradigm was used to discover senolytic drugs. Based on the observation that senescent cells release factors that cause apoptosis of the cells around them, yet are themselves resistant to apoptosis, Dr. Kirkland hypothesized that senescent cells utilize senescent cell anti-apoptotic pathways (SCAPs) for protection from their own senescence-associated secretory phenotype (SASP). Using bioinformatics analyses of senescent vs. non-senescent cells and RNA interference, Dr. Kirkland identified these SCAPs and verified their importance for senescent cell survival. Dr. Kirkland used bioinformatics approaches to identify agents that target key nodes across the SCAP network and demonstrated these drugs are senolytic in rodent and human cultured cells and mice in vivo. These senolytic drugs include Dasatinib (D), Quercetin (Q), Fisetin, Navitoclax, and related compounds. Dr. Kirkland showed these agents delay, prevent, or alleviate multiple disorders in mouse models of human chronic diseases and aging phenotypes. Conditions alleviated in mouse models include frailty, diabetes, hepatic steatosis, cirrhosis, renal dysfunction, neuropsychiatric disorders, dementias, pulmonary fibrosis, osteoporosis, osteoarthritis, retinal degeneration, diastolic dysfunction, cardiac ischemia, vascular hyporeactivity, infertility, and skin disorders, among others. He demonstrated that intermittent, orally administered senolytics reduce senescent cell abundance in adipose tissue and blood markers of senescent cell burden in blood of patients with diabetic kidney disease. He and collaborators found that a brief course of senolytics enhances physical function and reduces frailty in patients with idiopathic pulmonary fibrosis, a fatal, cellular-senescence-driven disease for which available treatments have been unsatisfactory. Multiple clinical trials are currently underway of the senolytics that Dr. Kirkland discovered. He is a scientific advisory board member for several companies and academic organizations. In addition to being President-Elect of AFAR, he has been a member of the National Advisory Council on Aging of the National Institutes of Health, and past chair of the Biological Sciences Section of the Gerontological Society of America. He holds honorary appointments at Boston University and the University of Groningen in the Netherlands. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism. If you would like to support our channel, we’d love a coffee ☕…thank you! https://www.buymeacoffee.com/mhealthspan You can also find us on YouTube at https://www.youtube.com/c/modernhealthspan